Their latest study proposed a combination therapy with simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) based on PEG-EV-Dox to selectively target both tumor-associated macrophages and melanoma cells. The gene discussed is IL13; the disease is neoplasm.